Results 231 to 240 of about 10,662,454 (348)

Hierarchical Targeting of TREM2+ Myeloid Cells via Acid‐Triggered OMVs Reprogram Immunosuppression and Suppress Osteolysis in Bone‐Metastatic TNBC

Advanced Science, EarlyView.
This study developed a hierarchical targeting nanoplatform, siTREM2@ETP‐PEOz‐OMVs, against triple‐negative breast cancer (TNBC) bone metastasis. It precisely delivers therapeutic siTREM2 to monocytes/macrophages within the metastatic niche. This intervention dually regulates cell fate: reprogramming immunosuppressive macrophages and inhibiting ...
Fanglu Chen, Yucheng Xue, Xiao Ma, Liang Chen, Zhenxuan Shao, Hangxiang Sun, Haochen Mou, Fangqian Wang, Zilong Li, Yechao Shen, Zhaoming Ye, Xiaohua Yu, Shengdong Wang   +12 more
wiley   +1 more source

Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study

Blood Cancer Journal
Yan-Yan Li, Shuai-Shuai Ge, Yuan-Hong Huang, Ming-Zhu Xu, Chao-Ling Wan, Kai-Wen Tan, Tao Tao, Hai-Xia Zhou, Sheng-Li Xue, Hai-Ping Dai   +9 more
doaj   +1 more source

Editorial: Practical recommendations and consensus for the management of immune mediated hematologic diseases. [PDF]

Front Immunol
Fattizzo B, Berentsen S, Barcellini W.
europepmc   +1 more source

The AUTACE That Degrades KRAS and Engages CD8+ T Cells for the Treatment of KRAS/TP53 Co‐Mutant Tumors

Advanced Science, EarlyView.
AUTACE is a bifunctional nanoplatform that integrates tumor targeting, immune engagement, and on‐demand KRAS degradation. It targets KRAS/TP53 co‐mutant tumors via TP53‐specific TCRs, elicits antitumor CD8+ T‐cell responses through surface anti‐CD3 antibodies, and uses low‐intensity focused ultrasound (LIFU) to trigger controlled release of the KRAS ...
Luo Li, Bolin Li, Yanan Hao, Bo Pang, Pan Li, Chunli Li, Yu Tang   +6 more
wiley   +1 more source

Performance of Large Language Models in Diagnosing Rare Hematologic Diseases and the Impact of Their Diagnostic Outputs on Physicians: Combined Retrospective and Prospective Study.

J Med Internet Res
Yu H, Chen T, Zhang X, Yang Y, Liu Q, Yang C, Shen K, Li H, Tang W, Zhong X, Shuai X, Yu X, Liao Y, Wang C, Zhu H, Wu Y.   +15 more
europepmc   +1 more source

Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM). [PDF]

Medicina (Kaunas)
Batinić J, Dreta B, Rinčić G, Mrdeža A, Jakobac KM, Krišto DR, Vujčić M, Piršić M, Jonjić Ž, Periša V, Sinčić Petričević J, Coha B, Holik H, Valković T, Stanić M, Krečak I, Stojanović A, Sajfert D, Bašić-Kinda S.   +18 more
europepmc   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Base Editors-Mediated Gene Therapy in Hematopoietic Stem Cells for Hematologic Diseases. [PDF]

Stem Cell Rev Rep
Zhang C, Xu J, Wu Y, Xu C, Xu P.
europepmc   +1 more source

A Dual‐Responsive Versatile Nanohybrid Orchestrating Tumor Elimination and Tumor‐Associated Osteolysis Restoration via Sequential Release

Advanced Science, EarlyView.
The versatile CaO2@CuMOF@HAP nanohybrid demonstrates an outstanding MMP9/pH‐triggered release performance for sequential release of osteogenic growth peptide into deep‐seated tumor‐infiltrated bone destruction areas and dual ions into tumor cells, enabling efficient tumor‐associated osteolysis restoration and tumor elimination for more comprehensive ...
Lan Liu, Han‐Zhe Liu, Zhe‐Nan Liu, Tong Wang, Li‐Li Yu, Qiu‐Jing Li, Zi‐Yi Chen, Guo‐Feng Luo, Zheng‐Jun Shang   +8 more
wiley   +1 more source

Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases. [PDF]

Biomedicines
Aurer I, Jakšić O, Bašić-Kinda S, Mišura-Jakobac K, Sinčić-Petričević J, Novaković-Coha S, Galušić D, Holik H, Valković T, Županić-Krmek D, Hude-Dragičević I, Milunović V, Pejša V.   +12 more
europepmc   +1 more source